DOCSLIB.ORG

Doping Control of Athletes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Doping Control of Athletes trends in analytical chemistry, vol. 7, no. IO, I988 375 trends Doping control of athletes E. G. de Jong*, I?. A. A. Maes and The definition of the Council of Europe for doping J. M. van Rossum is2: Utrecht, Netherlands ‘The administration to or the use by a healthy indi- vidual in any way of compounds which are not natu- History ral to the organism or the use of physiological com- The origin of the word doping is not certain. It first pounds in abnormal doses or in an abnormal way appeared in the English dictionaries at the end of the with the only purpose to artificially and dishonestly nineteenth century. The first reference to the use of influence the performance of this person during doping by athletes was in 1864 during swimming competition.’ competitions that were held in the canals of Amster- Another possible definition is: dam. The use of what is known as a ‘speedball’, a ‘The use of compounds which are not synthesized mixture of heroine and cocaine, by cyclists was de- by the human body or the use of endogenous com- scribed in 1869. In 1904 the Russian chemist pounds in excessive doses with the aim to improve Bukowski was able to identify some alkaloids in the performance in sport competitions.’ saliva of horses’. A simpler definition is: Australia was the first country to take measures ‘The use of forbidden drugs. ’ against doping in sports in 1962, and England fol- The last definition can only be used when we have lowed with the drugs bill in 1964. During the Olym- a clear and unambiguous list of forbidden drugs. The pic Games of Mexico (1968) the first doping control Medical Commission of the International Olympic tests were performed but it took another 10 years be- Committee (IOC) has decided which compounds fore the use of anabolic steroids could also be de- should be listed as ‘forbidden’ and fortunately most tected and tested for. international and national sport federations comply Doping is a topic that attracts a lot of publicity to the IOC rules. However, there are still some non- from the media, e.g. the cases of the athlete Sandra Olympic sports with their ‘own regulations, which can Gasser (1987), the skater Goeljajev (1988) and Ben lead to confusion. Johnson (during the Olympic games in Seoul). From the publications in the media it is obvious that doping Why doping control? is used in all kinds of sports including body building, The IOC started its doping control program for power lifting, cycling, athletics, skating, tennis and several reasons. First of all, all competitors should even billiards. Athletes such as Steve Cram and Carl have an equal chance and the use of doping should Lewis have openly attacked the current procedures therefore be forbidden. Secondly, the use of certain for doping control, asking for an even more stringent drugs can result in a decrease of motoric control but fair testing procedure. It should be impossible which can endanger the other competitors, e.g. cycl- for sportsmen to make arrangements with the orga- ists riding close together in a pack. Last but not least nization committees about doping control. Every is the possible risk of side-effects such as addiction to athlete should be tested during a competition. amphetamines or narcotics, or possible liver damage and cancer from anabolic steroids. Of course, it is al- What is doping? ways difficult to prove that certain side-effects result It is very difficult to find a satisfactory definition from the use of doping. Double-blind cross-over for doping. Many experts and committees have studies with athletes using anabolics are very diffi- spent valuable time trying to answer this question cult and to measure possible damage the follow-up without success. When does a cup of coffee becomes should continue for years. a forbidden drug instead of a socially accepted stimu- lant? Forbidden compounds and their use The current IOC list3,4 consists of five groups of * To whom correspondence should be addressed doping classes with forbidden drugs. 01659936/88/$03.00. 0 Elsevier Science Publishers B.V. 376 trends in analyticalchemistry, vol. 7, no. IO, 1988 (I) Stimulants bolic steroids. There are many medical indications According to their action, several groups of stimu- for the use of such anabolic steroids. In sports ana- lants can be discriminated although the boundaries bolics are used not only for increasing muscle mass between them are not clear and the classification but also to improve recuperation of the muscles after therefore debatable’. The most well known group of heavy physical strain. Also, they help injuries to heal stimulants is formed by the psychomotoric stimulants quicker. The potential severe side-effects - liver such as amphetamine. Amphetamine and its deriva- damage, impotency or cancer - are reduced by tives reduce the appetite, and feelings of fatigue. using lower doses of short-acting anabolics under the They can raise morale and self-confidence while im- control of a physician. However, high doses of sever- proving alertness, initiative and physical activity. al anabolics are still being used in sports such as pow- The known side-effects are headache, dizziness, hal- erlifting and bodybuilding. lucinations, but especially dangerous for athletes is the disturbance of body temperature regulation. The (IV) Beta-blocking agents characteristic reduced self-criticism also leads to un- In January 1987 the use of beta-blockers was for- necessary risks (also for other competitors). Exam- bidden. They were found to be used by ski-jumpers ples are amfepramone, benzphetamine, fencamfa- to calm their nerves, as well as in sports such as pen- min and propylhexedrine. Also the anorexic drugs thathlons, shooting and billiards. These drugs block such as fenfluramine and the central nervous system the beta-receptors in the heart resulting in a de- stimulants cocaine and pemoline belong to this creased cardiac rhythm. This can be useful in sports group. where aiming is important. Ephedrine and other phenylethylamines belong to the sympathicomimetics, a group of drugs which, like (V) Diuretics adrenaline stimulate the sympathetic nervous sys- The last group added to the list is the group of tem. Compounds that activate the central nervous masking agents, the diuretics. These drugs increase system are called analeptics and they are used to the urine volume thereby diluting the concentration stimulate respiratory functions (pentetrazol, beme- of the possible forbidden doping agents. In the ana- gride) or the heart (nikethamide, mefentermine, lytical analysis some compounds may well fall under strychnine). Caffeine is also regarded an analeptic the detection limit by this dilution. Diuretics are also drug. This socially accepted stimulant has been used used to lose weight quickly for placement in lower for centuries and millions of people need their daily weight categories in certain sports, e.g. judo, taek- dosis of caffeine; without it they get headaches or be- wondo, or weightlifting. During the Olympic games come moody. It is also known that caffeine will in- in Seoul four athletes were found positive on the di- crease the combustion of fat thereby saving the gly- uretic furosemide. cogen in the muscles which results in increased sta- Another compound that attracted a lot of atten- mina. tion in 1988 was probenecid. This compound reduces the excretion of antibiotics and steroids. It may well (II) Narcotics reduce the concentration of anabolic steroids in All narcotic analgesics are forbidden in sports. Be- urine to l-10%, thus making analysis impossible6. cause of their euphoric and analgesic effect these This compound has therefore been banned and is drugs are used to lengthen performance time. Be- easily detected in the screening procedures for stim- sides morphine, heroin, pethidine and dextropro- ulants and anabolic steroids (own results). poxyphene, codeine also belongs to this group which often leads to problems because it is present in many commonly used cough and cold preparations. Doping control regulations The procedures for doping control vary for differ- (III) Anabolic steroids ent sports, depending on the regulations of the inter- The use of hormones in sports is probably the most national sport federations such as the IAAF (athlet- well-known form of doping. The use of the male sex- ics) and UC1 (cycling). The legal situation is also dif- hormone testosterone increases protein synthesis ferent in each country. Five European countries take and therefore creates more muscle: the anabolic ef- legal action against doping: Belgium (1965), France fect. Androgenic effects also occur. Virilization ef- (1965), Italy (1971), Turkey (1971) and Greece fects are particularly obvious in women users. The (1976). In Switzerland, Germany and the Scandina- pharmaceutical industry has therefore synthesized vian countries the national sport federations have testosterone derivatives with less androgenic effects, strict regulations against doping. In the Netherlands but with high anabolic action: these are called ana- there is no law against doping as the government is trends in’analyticalchemhtry, vol. 7, no. lo,1988 377 TABLE I. Examples of forbidden drugs according to the IOC regulations Stimulants Amfepramone Clorprenaline Etilamfetamine Methylphenidate Pipradrol Amfetaminil Cocaine Fencamfamin Morazone Prolintane Amiphenazole Cropropamide’ Fenetylline Nikethamide Propylhexedrine Amphetamine Crotethamide” Fenproporex Pemoline Pyrovalerone Benzphetamine Dimetamfetamine Furfenorex Pentetrazol Strychnine Caffeine Ephedrine
Load more

Recommended publications
  • AO-Klasifikácia Faktúr →Zlomeniny
    AO-klasifikácia faktúr →zlomeniny. AOP-syndróm – skr. syndroma adipositas–oligomenorrhoea–parotis. aorta – [g. aorté srdcovnica] srdcovnica. Začína sa z ľavej komory a vystupuje kraniálne aţ do výšky 2. pravého sternokostálneho kĺbu ako aorta ascendens, pokračovaním je oblúk arcus aortae, aorta descendens, aorta thoracia a aorta abdominalis. Aorta ascendens – začína sa v ľavej komore nad polmesiačikovitými chlopňami a skoro celá sa nachádza v perikarde. Je dlhá asi 4 – 5 cm, jej priemer je 22 – 30 mm. Ihneď nad chlop-ňami je následkom spätných nárazov krvi mierne vydutá do tzv. sinus aortae, výraznejšie u starších osôb. Oddiely a. obsahujúce sinus aortae sa nazývajú bulbus aortae. U starších osôb býva následkom nárazov krvi širší aj koncový úsek vzostupnej a. pred jej prechodom do oblúka, tzv. sinus maximus (quartus) aortae. Tu býva u starších osôb a. často rozširená. A. ascendens, ako aj začiatok arcus aortae majú špeciálne vasa vasorum pochádzajúce z vencovitých tepien (aa. cardiaortales). Tento úsek osobitne patogeneticky rizikový. Začiatok aorta ascendens je ešte obalený vo vagina serosa arteriarum, kt. tvorí na ventrálnom obvode a. priečnu krkvu podloţenú subseróznym tukovým väzivom (Concatova-Bacceli tuková krkva). Vnútri vagina arteriarum je aorta ascendens a začiatrok a. pulmonalis spojené tuhým väzivom (vincula aortae Rindfleischi). Výstup aorta ascendens kryje spredu začiatok a. pulmonalis, ventrálne a vpravo je auricula dextra, dorzálne je uloţený r. dexter a. pulmonalis. Kraniálne vpravo od a. je v. cava superior, vľavo kmeň a. pulmonalis. Z ventrálneho a ľavého sinus aortae sa začína a. coronaria cordis dextra et sinistra. Aorta ascendens a arcus aortae Arcus aortae – je dlhý asi 6 cm, začína sa za sternom vo výške úponu 2.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • The 2014 Prohibited List International Standard
    The World Anti-Doping Code THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD Version 2.0 (revised 2014 version) The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 September 2014 The revised 2014 Prohibited List 17 May 2014 THE 2014 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 September 2014 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol;
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Gavinmclaughlin.Pdf (2.172Mb)
    Accepted for publication in Drug Testing and Analysis 13.04.2018 Synthesis, analytical characterization and monoamine transporter activity of the new psychoactive substance 4- methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers Gavin McLaughlin, a,b* Michael H. Baumann, c Pierce V. Kavanagh, a Noreen Morris, d John D. Power, a,b Geraldine Dowling, a,e Brendan Twamley, f John O’Brien, f Gary Hessman, f Folker Westphal, g Donna Walther, c and Simon D. Brandt h a Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James’s Hospital, James’s Street, Dublin 8, D08W9RT, Ireland b Forensic Science Ireland, Garda Headquarters, Phoenix Park, Dublin 8, D08HN3X, Ireland c Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Suite 4400, Baltimore, MD 21224, USA d Department of Life & Physical Sciences, Faculty of Science and Health, Athlone Institute of Technology, Dublin Road, Athlone, Co. Westmeath, N37HD68, Ireland e Department of Life Sciences, School of Science, Sligo Institute of Technology, Ash Lane, Sligo, F91YW50, Ireland f School of Chemistry, Trinity College Dublin, College Green, Dublin 2, D02EV57, Ireland g State Bureau of Criminal Investigation Schleswig-Holstein, Section Narcotics/Toxicology, Mühlenweg 166, D-24116 Kiel, Germany h School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK *Correspondence to: Gavin McLaughlin, Department of Pharmacology & Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James’s Hospital, James’s Street, Dublin 8, D08W9RT, Ireland. E-Mail: [email protected] Running title: Characterization of methylphenmetrazine isomers 1 Accepted for publication in Drug Testing and Analysis 13.04.2018 Abstract The availability of new psychoactive substances on the recreational drug market continues to create challenges for scientists in the forensic, clinical and toxicology fields.
    [Show full text]
  • Le Dopage Existe Dans Le Sport N'est Pas Un Scandale
    Le point sur les récentes affaires de dopage (1997-1999) Thierry-Roland Canizares To cite this version: Thierry-Roland Canizares. Le point sur les récentes affaires de dopage (1997-1999). Sciences pharma- ceutiques. 1999. dumas-01563861 HAL Id: dumas-01563861 https://dumas.ccsd.cnrs.fr/dumas-01563861 Submitted on 18 Jul 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. AVERTISSEMENT Ce document est le fruit d'un long travail approuvé par le jury de soutenance et mis à disposition de l'ensemble de la communauté universitaire élargie. Il n’a pas été réévalué depuis la date de soutenance. Il est soumis à la propriété intellectuelle de l'auteur. Ceci implique une obligation de citation et de référencement lors de l’utilisation de ce document. D’autre part, toute contrefaçon, plagiat, reproduction illicite encourt une poursuite pénale. Contact au SID de Grenoble : [email protected] LIENS LIENS Code de la Propriété Intellectuelle. articles L 122. 4 Code de la Propriété Intellectuelle. articles L 335.2- L 335.10 http://www.cfcopies.com/juridique/droit-auteur
    [Show full text]
  • Toxicology Report Division of Toxicology Daniel D
    Franklin County Forensic Science Center Office of the Coroner Anahi M. Ortiz, M.D. 2090 Frank Road Columbus, Ohio 43223 Toxicology Report Division of Toxicology Daniel D. Baker, Chief Toxicologist Casey Goodson Case # LAB-20-5315 Date report completed: January 28, 2021 A systematic toxicological analysis has been performed and the following agents were detected. Postmortem Blood: Gray Top Thoracic ELISA Screen Acetaminophen Not Detected ELISA Screen Barbiturates Not Detected ELISA Screen Benzodiazepines Not Detected ELISA Screen Benzoylecgonine Not Detected ELISA Screen Buprenorphine Not Detected ELISA Screen Cannabinoids See Confirmation ELISA Screen Fentanyl Not Detected ELISA Screen Methamphetamine Not Detected ELISA Screen Naltrexone/Naloxone Not Detected ELISA Screen Opiates Not Detected ELISA Screen Oxycodone/Oxymorphone Not Detected ELISA Screen Salicylates Not Detected ELISA Screen Tricyclics Not Detected Page 1 of 4 Casey Goodson Case # LAB-20-5315 GC/FID Ethanol Not Detected GC/MS Acidic/Neutral Drugs None Detected GC/MS Nicotine Positive GC/MS Cotinine Positive Reference Lab Delta-9-THC 13 ng/mL Reference Lab 11-Hydroxy-Delta-9-THC 1.2 ng/mL Reference Lab 11-Nor-9-Carboxy-Delta-9-THC 15 ng/mL Postmortem Urine: Gray Top Urine GC/MS Cotinine Positive This report has been verified as accurate and complete by ______________________________________ Daniel D. Baker, M.S., F-ABFT Cannabinoid quantitations in blood were performed by NMS Labs, Horsham, PA. Page 2 of 4 Casey Goodson Case # LAB-20-5315 Postmortem Toxicology Scope of Analysis Franklin County Coroner’s Office Division of Toxicology Enzyme Linked Immunosorbant Assay (ELISA) Blood Screen: Qualitative Presumptive Compounds/Classes: Acetaminophen (cut-off 10 µg/mL), Benzodiazepines (cut-off 20 ng/mL), Benzoylecgonine (cut-off 50 ng/mL), Cannabinoids (cut-off 40 ng/mL), Fentanyl (cut-off 1 ng/mL), Methamphetamine/MDMA (cut-off 50 ng/mL), Opiates (cut-off 40 ng/mL), Oxycodone/Oxymorphone (cut-off 40 ng/mL), Salicylates (50 µg/mL).
    [Show full text]
  • Les Femmes Peuvent Prendre Du Viagra * Achat De Viagra En
    Viagra est indiquée pour le traitement de la dysfonction érectile masculine. >>> ORDER NOW <<< Les femmes peuvent prendre du viagra Tags: cialis ou viagra acheter vrai ou faux viagra risques avec viagra acheter du viagra sans ordonnance en suisse danger du faux viagra comment bien prendre viagra le prix du viagra en pharmacie au maroc les effets indesirable du viagra que ce que viagra de gaulle contre le viagra achat viagra internet doctissimo commande viagra belgique peut on avoir du viagra en pharmacie sans ordonnance comment prendre sildenafil pfizer nitrates and viagra interaction ordonnance ou pas pour viagra notice demballage viagran quels sont les effets du viagra quelle quantité de viagra prendre peut on acheter viagra en pharmacie sans ordonnance comment avoir le viagra site sur achat viagra nitrates viagra can deadly combination Recession quest ce qui peut remplacer le viagra review am astonishingly forgetful. Some things said caffeine was fine to consume (in drinks, food, etc) while on the med, others said caffeine decreased the effects of the med. Features of this disorder include dysphonia, dysarthria, and loss of pain and temperature over the ipsilateral face and contralateral body. Jeg vil også erklære, at du forlader soap ud. If you feel very bored when waiting for something or someone (a bus, your friend, your kids), distract yourself with a book, magazine, or crossword puzzle. The celexa is longer acting and must build in the system over time in order to work for anxiety. Medscape is the leading online destination for healthcare professionals seeking clinical information. Paxil over time increased my appetite but i think that is because les femmes peuvent prendre du viagra made me tired and lethargic, they did not increase appetite, in fact in the first few months they curbed it right down.
    [Show full text]
  • University of Groningen Multi-Residue Analysis of Growth Promotors In
    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
    [Show full text]